^
    Back
    Association details:
    Biomarker:FGFR expression
    Cancer:Urothelial Cancer
    Drug:rogaratinib (BAY 1163877) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GU 2020
    Title:

    Phase I experience with rogaratinib in patients (pts) with urothelial carcinoma (UC) selected based on FGFR mRNA overexpression.

    Published date:
    02/14/2020
    Excerpt:
    Rogaratinib demonstrated a favorable safety and efficacy profile in pts with tumor FGFR1-3 mRNA-positive UC.
    Trial ID:
    NCT01976741
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway.

    Published date:
    05/16/2018
    Excerpt:
    Selection of pts for treatment with rogaratinib based on FGFR mRNA expression levels was feasible and identified drug-sensitive pts with and without underlying FGFR gene alterations. Rogaratinib had a favorable safety profile and showed promising anti-tumor activity in UC pts...
    DOI:
    10.1200/JCO.2018.36.15_suppl.4513
    Trial ID:
    NCT01976741